DDInter1763 DDInter1771
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) downregulates {v} (Gene) PPP2CA
PPP2CA {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Temsirolimus {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is downregulated by {v} (Compound) Ezetimibe
Ezetimibe {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Teriflunomide
Temsirolimus (Compound) downregulates PPP2CA (Gene) and PPP2CA (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temsirolimus (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Ezetimibe (Compound) and Ezetimibe may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide